ATE392903T1 - Impfstoff gegen pferdeherpesvirus - Google Patents

Impfstoff gegen pferdeherpesvirus

Info

Publication number
ATE392903T1
ATE392903T1 AT02713437T AT02713437T ATE392903T1 AT E392903 T1 ATE392903 T1 AT E392903T1 AT 02713437 T AT02713437 T AT 02713437T AT 02713437 T AT02713437 T AT 02713437T AT E392903 T1 ATE392903 T1 AT E392903T1
Authority
AT
Austria
Prior art keywords
herpes virus
vaccine against
equine herpes
against equine
vaccine
Prior art date
Application number
AT02713437T
Other languages
German (de)
English (en)
Inventor
Mark Mellencamp
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Application granted granted Critical
Publication of ATE392903T1 publication Critical patent/ATE392903T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02713437T 2001-03-20 2002-01-23 Impfstoff gegen pferdeherpesvirus ATE392903T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/812,720 US6803041B2 (en) 2001-03-20 2001-03-20 Equine herpesvirus vaccine

Publications (1)

Publication Number Publication Date
ATE392903T1 true ATE392903T1 (de) 2008-05-15

Family

ID=25210428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713437T ATE392903T1 (de) 2001-03-20 2002-01-23 Impfstoff gegen pferdeherpesvirus

Country Status (15)

Country Link
US (3) US6803041B2 (enExample)
EP (2) EP1372712B1 (enExample)
JP (2) JP4177112B2 (enExample)
KR (1) KR100840525B1 (enExample)
AR (2) AR032984A1 (enExample)
AT (1) ATE392903T1 (enExample)
CA (1) CA2441292C (enExample)
CY (1) CY1108200T1 (enExample)
DE (1) DE60226218T2 (enExample)
DK (2) DK1372712T3 (enExample)
ES (2) ES2305220T3 (enExample)
MX (1) MXPA03008287A (enExample)
NZ (1) NZ529012A (enExample)
PT (1) PT1372712E (enExample)
WO (1) WO2002074335A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
JP2005075752A (ja) * 2003-08-29 2005-03-24 Nippon Inst For Biological Science 豚繁殖・呼吸障害症候群用ワクチン製剤
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
BRPI0618041A2 (pt) * 2005-11-01 2011-08-16 Intervet Int Bv uso de um vìrus inativado da influenza eqüina, e, método para a proteção de eqüinos contra a infecção com influenza eqüina
US9642908B2 (en) 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
ES2675771T3 (es) 2008-12-16 2018-07-12 Ology Bioservices, Inc. Producción de vacunas contra el virus de la gripe
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
EP2569007B1 (en) * 2010-05-11 2015-10-14 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
ES2742325T3 (es) * 2013-05-14 2020-02-13 Zoetis Services Llc Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
US12258540B2 (en) 2017-10-30 2025-03-25 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
JP2018088928A (ja) * 2018-02-13 2018-06-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
CA3225885A1 (en) * 2021-08-06 2023-02-09 Sylvia REEMERS Vaccine for equine herpesvirus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4110433A (en) 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
US4083958A (en) 1976-09-13 1978-04-11 The University Of Kentucky Research Foundation Inactivated equine rhinopneumonitis virus vaccine and use thereof
US4225582A (en) 1979-03-08 1980-09-30 The University Of Illinois Foundation Vaccine for equine rhinopneumonitis
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US5084271B1 (en) 1984-09-11 1997-08-05 Univ Melbourne Vaccine for equine herpesvirus
US4758641A (en) 1987-02-24 1988-07-19 The B F Goodrich Company Polycarboxylic acids with small amount of residual monomer
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5221722A (en) 1988-11-28 1993-06-22 The B. F. Goodrich Company Crosslinked polyacrylic acid
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US6025181A (en) * 1990-07-06 2000-02-15 University Court Of The University Of Glasgow Equine herpesvirus-4TK mutant
DE69131984T2 (de) 1990-08-01 2000-07-06 Research Corp. Technologies, Inc. Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
EP0532833A1 (en) 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
DE69333416D1 (de) 1992-06-01 2004-03-18 Univ Melbourne Parkville Immunologisches Verfahren für die Detektion von Pferde-Herpesvirus Typ 1 und 4 glycoprotein G Antikörper
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
US6225111B1 (en) * 1992-08-07 2001-05-01 Schering Plough Veterinary Corp. Recombinant equine herpesviruses
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US5853715A (en) * 1996-08-16 1998-12-29 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
JP2002504227A (ja) 1997-03-12 2002-02-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング クロマトグラフィーカラムの末端部材
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
EP0978286A1 (en) 1998-08-07 2000-02-09 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine

Also Published As

Publication number Publication date
AR091235A2 (es) 2015-01-21
DE60226218T2 (de) 2009-05-28
JP4668951B2 (ja) 2011-04-13
EP1372712A2 (en) 2004-01-02
WO2002074335A3 (en) 2003-07-17
DE60226218D1 (de) 2008-06-05
NZ529012A (en) 2005-08-26
WO2002074335A2 (en) 2002-09-26
EP1923071A1 (en) 2008-05-21
JP2007197470A (ja) 2007-08-09
CA2441292C (en) 2012-03-20
EP1372712B1 (en) 2008-04-23
US7226604B2 (en) 2007-06-05
AR032984A1 (es) 2003-12-03
MXPA03008287A (es) 2004-10-28
US20050084502A1 (en) 2005-04-21
US20070196390A1 (en) 2007-08-23
KR100840525B1 (ko) 2008-06-24
US6803041B2 (en) 2004-10-12
CY1108200T1 (el) 2014-02-12
PT1372712E (pt) 2008-05-29
CA2441292A1 (en) 2002-09-26
KR20030085028A (ko) 2003-11-01
DK1372712T3 (da) 2008-08-04
JP2004525923A (ja) 2004-08-26
JP4177112B2 (ja) 2008-11-05
EP1923071B1 (en) 2013-06-19
ES2305220T3 (es) 2008-11-01
ES2428664T3 (es) 2013-11-08
DK1923071T3 (da) 2013-08-26
US20030206924A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
DE60024893D1 (de) Impfstoff gegen HPV
CY2016018I1 (el) Εμβολιο κατα του ιου του δυτικου νειλου
ATE287728T1 (de) Adjuvierte rekombinante lebendimpfstoffe gegen influenza- oder herpesviren
DK1390066T3 (da) Vaccinesammensætning
NO20021431D0 (no) Intranasal influensavirusvaksine
DK1427444T3 (da) West-nil-vaccine
ATE420159T1 (de) Grippe-impfstoffzusammensetzung
NO20044326D0 (no) Virale antigener
EP1458242A4 (en) COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
NO20031483D0 (no) Vaksine
ATE275631T1 (de) Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff
NO20024172L (no) Vaksine
EP1307130A4 (en) VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
DK1523329T3 (da) Viruspartikeladjuvant
NO20033882D0 (no) Vaksine
EP1423141A4 (en) VACCINE
NO20030239L (no) Modifisert virus
IS7831A (is) Bóluefni
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
EP1692279A4 (en) VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
NO20033829L (no) Virusdrepende preparater
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
DE60125927D1 (de) Impfstoffe gegen hiv
IS6184A (is) Bóluefni gegn ISA veiru

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1372712

Country of ref document: EP